Provided by Tiger Fintech (Singapore) Pte. Ltd.

Urogen Pharma Ltd.

11.47
-0.1700-1.46%
Volume:345.20K
Turnover:3.92M
Market Cap:528.70M
PE:-3.88
High:11.60
Open:11.53
Low:11.15
Close:11.64
Loading ...

Guggenheim Keeps Their Buy Rating on Urogen Pharma (URGN)

TIPRANKS
·
29 Apr

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?

Zacks
·
29 Apr

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Trade Tensions Persist

MT Newswires Live
·
28 Apr

Top Premarket Gainers

MT Newswires Live
·
28 Apr

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
28 Apr

UroGen Pharma Reports Nearly 4-Year Response for Urothelial Cancer Therapy -- Shares Up Pre-Bell

MT Newswires Live
·
28 Apr

UroGen Pharma announces patient-reported outcomes on UGN-102

TIPRANKS
·
28 Apr

UroGen Pharma announces long-term follow up data from OPTIMA II Phase 2b study

TIPRANKS
·
28 Apr

UroGen Pharma reports long-term follow-up study with JELMYTO

TIPRANKS
·
28 Apr

UroGen Pharma announces results from Phase 1 study of UGN-301

TIPRANKS
·
28 Apr

UroGen Pharma announces updated 18-month DOR data from Phase 3 ENVISION trial

TIPRANKS
·
28 Apr

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

Business Wire
·
28 Apr

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

Business Wire
·
28 Apr

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

Business Wire
·
28 Apr

Urogen Announces Updated 18-Month Duration Of Response (Dor) Of 80.6% From The Phase 3 Envision Trial Of Ugn-102

Reuters
·
27 Apr

UroGen Pharma Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
18 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Grocery Outlet, Abbott, General Dynamics

Reuters
·
17 Apr

UroGen Pharma Initiated at Sector Outperform by Scotiabank

Dow Jones
·
16 Apr

Scotiabank Initiates UroGen Pharma at Sector Outperform With $23 Price Target

MT Newswires Live
·
16 Apr

Urogen Pharma Ltd : Scotiabank Initiates Coverage With Sector Outperform Rating; Target Price $23

THOMSON REUTERS
·
16 Apr